← FDA DRUG APPROVALS

FDA ANDA · ANDA075493

VINCRISTINE SULFATE PFS

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA075493
TYPE
ANDA
ORIGINAL APPROVAL
1999-09-01
LATEST ACTION
2020-11-25
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

VINCRISTINE SULFATE PFSDiscontinued
VINCRISTINE SULFATE 1MG/ML · INJECTABLE · INJECTION

Approval history

2020-11-25Labeling · Supplement 39 · standardAP
2020-11-25Labeling · Supplement 41 · standardAP
2015-08-31Labeling · Supplement 23AP
2015-08-31Labeling · Supplement 38 · standardAP
2015-08-31Labeling · Supplement 29 · standardAP
2013-05-13Labeling · Supplement 30 · standardAP
2012-01-23Labeling · Supplement 22AP
2002-09-17Labeling · Supplement 1AP
1999-09-01OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →